Nykredit A/S’s Viridian Therapeutics VRDN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$26.1K Hold
1,268
– – ﹤0.01% 1647
2026
Q2
$23.3K Buy
+1,268
New +$20.4K ﹤0.01% 1694

Other funds holding VRDN

Nykredit A/S's VRDN Position: Q3 2026 in Review

Nykredit A/S held its Viridian Therapeutics (VRDN) position steady in Q3 2026 at 1,268 shares worth $26.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1647.

Nykredit A/S first reported a position in VRDN in Q2 2026 and has held it in 2 quarters since. 235 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.

  • Nykredit A/S held 1,268 shares of Viridian Therapeutics worth $26.1K as of Q3 2026.
  • Nykredit A/S left its Viridian Therapeutics share count unchanged in Q3 2026.
  • Viridian Therapeutics made up ﹤0.01% of Nykredit A/S's portfolio in Q3 2026, its #1647 holding.
  • Nykredit A/S first reported a position in Viridian Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 235 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.

Based on Nykredit A/S's 13F filing for Q3 2026, filed 6 Nov 2026.